OpenClaim

Tarlatamab Side Effects

The most commonly reported side effects of tarlatamab include cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and off label use, based on 1,194 FDA adverse event reports from 2023 to 2025.

#1 Reported: Cytokine Release SyndromeAll side effects ↓Top Co-Medication: AtezolizumabDrug interactions ↓51% of Reports Are AdultDemographics ↓

Tarlatamab side effects

Percentages show how often each reaction appears relative to total reports for tarlatamab.

1
Cytokine Release Syndrome35.4%423
2
Immune Effector Cell-associated Neurotoxicity Syndrome16.8%200
3
Off Label Use14.7%176
4
Small Cell Lung Cancer9.2%110
5
Pyrexia9.0%108
6
Death8.6%103
7
Disease Progression5.0%60
8
Metastases To Central Nervous System4.3%51
9
Decreased Appetite3.1%37
10
Fatigue2.7%32
11
Dysgeusia2.5%30
12
Taste Disorder2.4%29
13
Hypotension2.3%27
14
Headache1.9%23
15
Metastases To Liver1.8%22

These are voluntary reports and do not establish that tarlatamab caused these reactions.

Report severity

83.2%Serious993 reports
27.6%Hospitalizations329 reports
16.8%Fatal201 reports

Seriousness is determined by the reporter, not by OpenClaim.

Tarlatamab drug interactions

Other drugs that appear in adverse event reports alongside tarlatamab. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.

Also suspected

1
Atezolizumab0.7%8
2
Etoposide0.6%7
3
Carboplatin0.4%5
4
Durvalumab0.2%2
5
Dexamethasone0.2%2
6
Irinotecan-hydrochloride0.2%2
7
Prednisone0.2%2
8
Oxycodone0.2%2
9
Filgrastim0.2%2
10
Olanzapine<0.1%1
11
Elacestrant-hydrochloride<0.1%1
12
Lurbinectedin<0.1%1
13
Darbepoetin-alfa<0.1%1
14
Cisplatin<0.1%1
15
Tocilizumab<0.1%1

Taken alongside

1
Dexamethasone3.8%45
2
Acetaminophen1.8%22
3
Tocilizumab1.3%15
4
Oxycodone1.2%14
5
Carboplatin1.1%13
6
Sodium-chloride0.9%11
7
Etoposide0.9%11
8
Durvalumab0.7%8
9
Atezolizumab0.6%7
10
Ondansetron0.6%7
11
Apomorphine-hydrochloride0.6%7
12
Oxygen0.6%7
13
Pantoprazole-sodium0.6%7
14
Levetiracetam0.5%6
15
Aspirin0.5%6

Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.

Who reports tarlatamab side effects

28.6% of tarlatamab adverse event reports involve female patients and 38.0% involve male patients. The largest age group is adult at 51%. These figures reflect who reports side effects, not underlying risk.

Sex

Female28.6%
Male38.0%
Unknown33.3%

Age group

< 20.0%
2–110.1%
12–170.6%
18–6450.6%
65+48.6%

What is tarlatamab used for

Conditions and purposes for which patients were taking tarlatamab when the adverse event was reported.

Bladder CancerCarcinoid Tumour PulmonaryColon CancerGastrointestinal Neuroendocrine TumourLarge Cell Lung Cancer MetastaticLung Neoplasm MalignantMedullary Thyroid CancerMetastases To Biliary TractMetastases To BoneMetastases To Central Nervous SystemMetastases To LiverNeoplasm MalignantNeuroendocrine Breast TumourNeuroendocrine CarcinomaNeuroendocrine Carcinoma Of Prostate

Showing 15 of 34 indications

Tarlatamab brand names and reporting trend

Tarlatamab is sold under the brand name Imdelltra.

Brand names

Imdelltra246

Quarterly reports (2023–2025)

20232025

An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.

Taking tarlatamab with another medication?

Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.

Check my medications